CBD Powder vs Oil: What a 2026 Human Study Found

“CBD powder versus oil” sounds like a simple contest, but products within each category can be made differently. A study published March 26, 2026 offers a more precise comparison: one encapsulated powdered CBD emulsion and one prescription CBD oil, each tested after a single dose under fed and fasted conditions.

The trial adds human data to a topic often reduced to marketing claims. It measured blood concentrations and timing, not whether either product improved symptoms or was preferable for everyday use. Researchers use the term pharmacokinetics for this type of measurement: how much of a compound and its metabolites appear in blood, and when. Those are useful but narrower questions than a person's day-to-day experience.

How the comparison worked

Researchers randomized 32 healthy adults into a four-period crossover trial. Participants received a 400-milligram CBD dose of CBtru powder in capsules and the oil-based Epidyolex formulation, each once after fasting and once after a standardized high-fat meal. Blood tests tracked CBD and its metabolites. The crossover design allowed the same people to contribute data for the different conditions.

That 400-milligram research dose is much higher than the 30 milligrams CBD listed per scoop on Jane's Brew's Nano CBD Powder. The study products were also specific formulations. It did not include Jane's Brew powder, and its results cannot be transferred to every CBD powder or oil.

What changed in the blood measurements

The powdered formulation reached its median peak CBD concentration earlier than the oil: three hours versus three and a half hours while fasted, and five hours versus eight hours after the high-fat meal. The study also found differences in metabolite exposure and variation between participants.

The more important nuance is total CBD exposure. Under fed conditions, the two formulations had similar overall CBD exposure over the measurement period. Under fasted conditions, the powder's CBD exposure was numerically higher, but that difference did not meet the study's threshold for statistical significance. This does not support the blanket claim that “powder is more bioavailable than oil.” It shows that the particular formulations and meal conditions changed some pharmacokinetic measures.

What remains unanswered

The trial involved healthy adults, one dose level, and single administrations, with blood sampling limited to 24 hours. It was designed around pharmacokinetics and short-term tolerability, not long-term use or clinical outcomes. Product-specific ingredients, manufacturing, and serving sizes could all affect whether another formulation behaves similarly.

For shoppers, the takeaway is to compare labels and serving amounts rather than assume all products with the same format perform alike. Research on how a product moves through the body is valuable, but it is a separate question from what a person will experience. Reading the exact study method keeps a useful finding from becoming an unsupported promise.